Victor van Beusechem

PROF.DR., (Principal Investigator)

1989 …2023

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


oncolytic immunotherapy, therapeutic target discovery, high-throughput functional genomic screening, cancer therapy development 


Research interests

The ultimate goal of the applied research in my laboratory is to make new, more effective medicines available for treatment of cancer patients. Towards this goal, two main strategies are followed.

Therapeutic target discovery: We perform high-throughput functional genomic screens with RNAi libraries to identify vulnerabilities in cancer cells. Next, we use validated leads from completed screens to discover new anticancer drugs and to design new treatment strategies.

Oncolytic immunotherapy: We apply molecular knowledge of cancer and viruses to develop next-generation oncolytic adenoviruses for personalized therapeutic vaccination. These viruses replicate in and kill cancer cells selectively, thereby inducing an adaptive immune response against released tumor antigens. We focus on promoting lytic replication and counteracting immune suppression in the tumor microenvironment. 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

PhD, Gene Therapy for Adenosine Deaminase Deficiency: Preclinical Studies, Leiden University, Leiden, Netherlands

Award Date: 16 Sept 1993

External positions

President, Netherlands Society of Gene and Cell Therapy

15 Mar 201831 Dec 2099

Chief Scientific Officer, ORCA Therapeutics

1 May 200831 Dec 2099

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or